Stock-research Ratings: Intra-Cellular Therapies, Inc. (ITCI), BlueLinx Holdings Inc. (BXC)

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) tinted gains of +3.28% (+0.43 points) to US$13.55. The volume of 0.23 Million shares climbed down over an trading activity of 404.52 Million shares. EPS ratio determined by looking at last 12 month figures is -2.67. Over the same time span, the stock marked US$25.82 as its best level and the lowest price reached was US$10.21. The corporation has a market cap of US$722.35 Million.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)’s earnings per share has been growing at a 6.3 percent rate over the past 5 year when average revenue increase was noted as -39.8 percent. The return on equity ratio or ROE stands at -35.7 percent while most common profitability ratio return on investment (ROI) was -22.6 percent. The company’s institutional ownership is monitored at 79.5 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 4 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.56. 5 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

BlueLinx Holdings Inc. (NYSE:BXC) is worth US$279.59 Million and has recently risen 5.43% to US$30.49. The latest exchange of 0.1 Million shares is below its average trading activity of 150.85 Million shares. The day began at US$29.09 but the price moved to US$29.09 at one point during the trading and finally capitulating to a session high of US$30.95. The stock tapped a 52-week high of US$46.42 while the mean 12-month price target for the shares is US$10.

Currently, the stock carries a price to earnings ratio of 5.73, a price to book ratio of 127.04, and a price to sales ratio of 0.11. For the past 5 years, the company’s revenue has grown -1%, while the company’s earnings per share has grown 37.1%. With an institutional ownership near 81.1%, it carries an earnings per share ratio of 5.32.